This is also the first report showing a significant influence of the SLC15A2 genotype on the response to sorafenib in patients with HCC; our results suggest that SLC15A2 is a novel gene involved in sorafenib metabolism. Here, SLC15A2 is linked to hepatocellular carcinoma.